Cassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's Trials
Cassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's Trials
Cassava Sciences Inc (NASDAQ:SAVA) stock is trading lower on Wednesday on a heavy session volume of 14.35 million, as per data from Benzinga Pro.
根據Benzinga Pro的數據，Cassava Sciences Inc.（納斯達克股票代碼：SAVA）的股票週三以成交量1435萬的重擊交易下跌。
The Board of Directors appointed Richard (Rick) Barry as Executive Chairman and the company's principal executive officer, effective immediately. The company is searching for a new permanent CEO.
董事會立即任命Richard（Rick）Barry爲執行主席和公司首席執行官。該公司正在尋找新的永久性CEO。
Mr. Barry succeeds Remi Barbier, the Company's Chairman, President, and CEO, who resigned and will remain employed by the Company until September 13, 2024, in a non-executive capacity, without duties or responsibilities.
Barry先生接替了Remi Barbier（公司的主席，總裁兼CEO），後者辭去了職務，並將在2024年9月13日之前以非行政職務的形式繼續受僱於公司，沒有義務或責任。
Lindsay Burns, SVP of Neuroscience at Cassava, is also leaving the company. Cassava and Dr. Burns have agreed that she step down from her role with the company, effective immediately.
Cassava的神經科學高級副總裁Lindsay Burns也將離開公司。Cassava和Burns博士已同意，她立即辭去公司職務。
Following her separation from the company and for a one-year period, Dr. Burns will furnish consulting services as and to the extent reasonably requested by Cassava to provide information and support for scientific research and/or obtain governmental approval for the company's products.
在與公司分離後的一年內，Burns博士將根據Cassava的合理要求提供諮詢服務，爲科學研究和/或獲得政府對公司產品的批准提供信息和支持。
Cassava may, at its sole discretion, extend the term of the consulting agreement by up to an additional year.
Cassava可以自行決定將諮詢協議的期限延長至多一年。
Related: Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation.
相關：Cassava Sciences與司法部和證券交易委員會合作，調查備受爭議的阿爾茨海默病藥物。
Mr. Barry said. "While our priority remains the development of a potentially effective treatment for Alzheimer's disease, the Board has a steadfast commitment to doing so with transparency, accountability, and highest ethical business practices." Among the actions the company is taking are:
Barry先生表示：“雖然我們的重點仍然是開發一種可能有效的治療阿爾茨海默病的藥物，但董事會致力於透明、負責任和最高的道德商業實踐。” 該公司正在採取的行動包括：
- New Leadership: The Board plans to separate the Chairman and CEO roles after identifying a new CEO.
- Single-minded Commitment to Scientific Rigor and Honest Transparency: The company's mission is to evaluate simufilam as a groundbreaking Alzheimer's treatment, focusing on scientific rigor and transparency with patients, government agencies, and investors. All study results will be promptly and accurately posted on clinicaltrials.gov.
- Rigorous Clinical Trials: The ongoing Phase 3 trials adhere to FDA and industry standards to ensure the integrity of results. Under the FDA-reviewed protocols, no company personnel know or will know which subjects receive the drug or placebo.
- Blinding information is maintained by a small group at CRO, Premier Research. Additionally, company personnel do not have access to sub-study results or other data that could reveal which patients are on placebo.
- All data is sent directly to Premier Research. Statistical analyses are conducted by professional biostatisticians at Pentara Corporation, with trial results transmitted to them independently by the CRO, without company involvement.
- Transparency in Communications and Reporting: Cassava is dedicated to maintaining transparent communication with its stakeholders. The company will resume quarterly analyst calls and ensure management is accessible to journalists. Cassava is also reviewing its disclosure practices to provide clear, comprehensive information. Ongoing dialogues with shareholders, employees, customers, regulators, and the community will shape the company's governance practices.
- 新領導：董事會計劃在找到新的CEO後分開董事長和CEO職位。
- 堅定不移地致力於科學嚴謹和真誠透明：“公司的使命是評估Simufilam作爲突破性的阿爾茨海默病治療，着重於向患者、政府機構和投資者進行科學嚴謹和透明的交流。所有研究結果將及時準確地發佈在clinicaltrials.gov上。”
- 嚴格的臨床試驗：正在進行的三期試驗遵循FDA和行業標準，以確保結果的完整性。根據經過FDA審核的協議，公司員工不知道或不會知道哪些受試者接受藥物或安慰劑。
- 掩蓋信息由CRO Premier Research的一小組維護。此外，公司人員無權訪問子研究結果或可能透露哪些患者接受安慰劑的其他數據。
- 所有數據直接發送到Premier Research。Pentara Corporation的專業生物統計學家進行統計分析，試驗結果是由CRO獨立傳輸給他們的，公司沒有參與其中。
- 透明的溝通和報告：Cassava致力於與其利益相關者保持透明的交流。公司將恢復每季度的分析師電話會議，並確保管理層可以被新聞界接觸到。爲了提供清晰全面的信息，Cassava還正在審查其披露實踐。公司的治理實踐將根據股東、員工、客戶、監管機構和社區的持續對話而形成。
Price Action: SAVA shares are down 27.20% at $9.85 at the last check on Wednesday.
價格行動：週三最後一次檢查表示SAVA股價下跌27.20％，至9.85美元。
- Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report.
- "嚴厲”的FDA檢查報告發布後，阿爾茨海默病藥物試驗結果受到質疑。
譯文內容由第三人軟體翻譯。